Shots:

• Organon has signed a definitive agreement to acquire Dermavant (a Roivant company), extending its international dermatology capabilities across the US
• The acquisition will add Dermavant’s VTAMA (tapinarof) cream, 1% intended for topical treatment of mild, moderate & severe plaque psoriasis in adults with its sNDA for AD in adults & children (≥2yrs.) under US FDA’s review (PDUFA: Q4’24). Dermavant holds global rights of the product (excl. China) and has out licensed Japan rights
• Under the agreement, Dermavant will receive a total of ~$1.2B which includes $175M upfront, $75M regulatory milestones for VTAMA cream in AD & $950M commercial milestones plus net-sales based royalties. Closing is anticipated during Q4’24

Ref: Organon | Image: Dermavant

Related News:- Dermavant Reports P-III Study (ADORING 1) Results of Vtama (tapinarof) for Adults and Children with Atopic Dermatitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com